In numerical terms, our latest recon of private market investment in the life sciences is about on par with the previous week: 13 deals with a total value of $987 million.
But there was a noticeable difference on the focus of the deals. Drugmakers (mostly in the biotechnology space) took the lion's share of funding in our previous tallies, but this time much of the funding accrues to digital health . . .
Continue Reading
Unlock this article instantly, along with the rest of our premium content and benefits including daily/weekly/monthly newsletters.
Monthly
$30
A pay-as-you-go plan to get you started
→ Instantly unlock all new and archived articles
→ Daily, weekly and monthly e-mail newsletters
→ Access to the weekly AW Deal Watch by AW Research
Annual
$300
Required for access to AW Research
Get more for less - 20% discount over monthly
→ Everything in Monthly PLUS:
→ Access to articles and data from AW Research
→ AW Annual Investor Compendium – our comprehensive guide to investor activity, with a ranking of the most active investors for the year and profiles of the top global allocators
